Introduction
Adult T-cell leukemia/lymphoma (ATLL) is a malignant and fatal disorder of CD4 þ T cells that is caused by infection of these cells with human T-cell leukemia virus type I (HTLV-1). ATLL occurs in 3-5% of HTLV-1 carriers following a long latency period, which can range from 40 to 60 years (Yasunaga and Matsuoka, 2003) . ATLL cells are derived from the malignant clonal expansion of an HTLV-1-infected CD4 þ T lymphocyte that has accumulated genetic lesions, including the activation of oncogenes or inactivation of tumorsuppressor genes (Tsukasaki et al., 2001) . A previous study from our laboratory discovered these genetic lesions by spectral karyotyping with a high-density single-nucleotide polymorphism array and comparative genomic hybridization in ATLL; we found that the T-cell transcription factor (TCF8)/zinc-finger E-box binding homeobox 1 (ZEB1) was a candidate tumor suppressor in ATLL (Hidaka et al., 2008) .
Transcription factors from the ZEB family have been characterized as downstream effectors of the transforming growth factor-b (TGF-b) signaling pathway. ZEB1 binds to receptor-regulated Smad2/3 and synergizes with Smadmediated transcriptional activation (van Grunsven et al., 2001; Postigo, 2003) . TGF-b1 belongs to a superfamily of cytokines that regulates a broad range of cellular responses, including cell proliferation, differentiation, adhesion, migration and apoptosis (Kingsley, 1994) . Deregulated TGF-b1 signaling has been implicated in various human diseases, including autoimmune diseases, vascular disorders and cancer (Blobe et al., 2000) . TGF-b1 has antiproliferative effects in a variety of cell types, and this negative regulation of cellular proliferation by TGFb1 functions to suppress the growth of tumor cells (Derynck et al., 2001) . However, HTLV-1-infected T cells and ATLL cells are resistant to the growth inhibitory action of TGF-b1, even though these cells express high levels of TGF-b1 (Kim et al., 1990) . Although Tax, a viral protein, has been reported to render cells resistant to TGFb1-mediated growth suppression (Mori et al., 2001; Arnulf et al., 2002) , Tax expression is not detectable in most ATLL cells. Therefore, it has been suggested that ATLL cells develop different mechanisms of resistance to escape the antiproliferative signal that is mediated by TGF-b1. One such mechanism might be associated with aberrant expression of MEL1S (Yoshida et al., 2004) , which was originally isolated as the gene that was transcriptionally activated by t(1;3)(p36;q21) in acute myeloid leukemia (Mochizuki et al., 2000) . We previously reported that ZEB1 expression was downregulated in a majority of ATLL cells (Hidaka et al., 2008) . Furthermore, ZEB1-mutant mice frequently developed CD4 þ T-cell lymphomas and/or leukemias, suggesting that ZEB1 may have a tumor suppressive role in ATLL. In addition, the enforced expression of ZEB1 partially restored the responsiveness of ATLL cells to TGF-b1. Therefore, the downregulation of ZEB1 expression may be associated with resistance to the growth inhibitory activity of TGF-b1.
In this paper, we report that Smad7, an inhibitory Smad (I-Smad), is overexpressed in HTLV-1-infected T-cell lines and primary leukemia cells from acute-type ATLL patients. Smad7 is immediately induced after TGF-b stimulation and acts as an antagonist of TGF-b signaling, which may regulate the intensity or duration of its signaling cascade (Shi and Massague´, 2003) . Although constitutive expression of Smad7 inhibited TGF-b1 growth suppression in ATLL cells, we found that ectopically expressed ZEB1 overcame the Smad7-mediated inhibition of TGF-b1 signaling. Smad7 constitutively bound to the promoter of the TGF-b1 responsive genes with the Smad-responsive element (SRE) to inhibit TGF-b1 signaling. TGF-b1 stimulation, in the presence of ZEB1 overexpression, led to ZEB1 recruitment of the Smad3 complex to the promoter region with Smad7 to reactivate TGF-b1 signaling. Conversely, ZEB1 mRNA was expressed in CD4
þ T cells in the late stages of T-cell development, and using CTLL2, a murine T-lymphoma cell line with ZEB1 expression, we examined the protein complexes associated with the promoter region of the TGF-b1 responsive genes with SRE and time course for gene expression of the TGF-b1 activating genes Smad6, Smad7, plasminogen activator inhibitor 1 (PAI-1) and cyclin-dependent kinase inhibitor 1A (p21). We found that a ternary complex of Smad3, Smad7 and ZEB1 on the p21 promoter with the SRE kept activating p21 transcription after the induction of Smad7 by TGF-b1. TGF-b1 stimulation of CTLL2 cells expressing a short hairpin to ZEB1 led to a shorter expression time interval of PAI-1 and p21 whereas the expression of Smad6 and Smad7 remained unchanged. The results suggest that ZEB1 enhances TGF-b1 signaling by binding not only to the Smad3 complex and but also to Smad7 in the nucleus. Thus, ZEB1 may have important roles in the regulation of TGF-b1 signaling, and both ZEB1 downregulation and Smad7 overexpression may be important molecular events that contribute to resistance to TGF-b1 signaling in ATLL.
Results

Upregulated expression of I-Smad7 in ATLL cells
We previously reported that ZEB1 expression was downregulated and functioned as a possible tumor suppressor in a majority of ATLL cells (Hidaka et al., 2008) . ZEB1 has been reported to bind Smad3 and enhance TGF-b1 signaling, and the resistance of HTLV-1-infected T cells and ATLL cells to TGF-b1-mediated growth inhibition is one of the most prominent characteristics of ATLL. Because ectopic expression of ZEB1 in ATLL cells partially restored sensitivity to TGF-b1, the mRNA expression of four Smad family members (Smad2, 3, 6 and 7) that function as modulators of TGF-b1 signaling were analyzed using semiquantitative RT-PCR in four HTLV-1-negative T-acute lymphoblastic leukemia (T-ALL) cell lines (MOLT4, MKB1, KAWAI and Jurkat) (referred as HTLV-1 (À)) and seven HTLV-1-positive cell lines (HTLV-1 ( þ )). These HTLV-1 ( þ ) cell lines included two HTLV-1-infected cell lines (MT2 and Hut102) and five ATLL-derived cell lines (ED, KOB, SO4, KK1 and S1T) (Figure 1a) . The MOLT4 cells and all seven HTLV-1 ( þ ) cell lines had high expression of inhibitory Smad7, but not of Smad6 mRNA, whereas the other three HTLV-1 (À) cell lines (MKB-1, KAWAI and Jurkat) did not express Smad7 but expressed Smad6. In addition, there were no significant differences in the pattern of Smad2 and Smad3 expression between the HTLV-1 (À) and HTLV-1 ( þ ) cell lines. Because HTLV-1 tax/rex mRNA was expressed in two HTLV-1-infected cell lines (MT2 and Hut102) and two ATLLderived cell lines (KOB and SO4), the expression patterns of HTLV-1 tax/rex did not appear to correlate with the expression of the four members of the Smad family. To confirm that protein levels of ZEB1, Smad3 and Smad7 correlate with the mRNA level in the leukemia cell lines, we analyzed protein expression by western blot (Supplementary Figure 1) . In HTLV-1 ( þ ) cells, we detected a significantly higher and lower expression level of Smad7 and ZEB1 mRNA and protein, respectively, compared to HTLV-1 (À) cells.
Next, we used real-time RT-PCR analysis to determine the quantitative expression levels of Smad7 and ZEB1 in the same 11 cell lines. The expression of Smad7 mRNA in the HTLV-1 ( þ ) cell lines and the MOLT4 cell line was significantly higher (Po0.05) than in the HTLV-1 (À) cell lines. However, the expression of ZEB1 mRNA was significantly reduced in the HTLV-1 ( þ ) cell lines (Figure 1b) . The Smad7/ZEB1 expression ratio was 10-fold greater in the HTLV-1 ( þ ) cell lines and the MOLT4 cell line compared to the CD4 þ T lymphocytes from normal volunteers. To confirm the expression pattern of high Smad7 with low ZEB1 in ATLL cells from patient samples, we used real-time RT-PCR using RNA isolated from ATLL cells derived from eight acute-type ATLL patients and normal CD4 þ T lymphocytes. As observed with the cell lines, all ATLL cells from patients with acute-type ATLL had higher Smad7/ZEB1 ratios than the CD4 þ T lymphocytes from normal volunteers (Po0.05) (Figure 1c ). In two patients (no. 4 and 7), the expression of Smad7 was almost equal to the level in normal CD4 þ T cells; however, the expression of ZEB1 was clearly decreased, suggesting that the reduction of ZEB1 may contribute to a part of the resistance to TGF-b1 signaling. Alternatively, Smad6 was weakly expressed in one out of eight ATLL cells and was not expressed in the CD4 þ T lymphocytes from normal volunteers (Supplementary Figure 2) . Therefore, these data suggest that the higher expression Figure 2a ) and quantitative RT-PCR (Figure 2b ). Approximately 70% of the parental and MOLT4-shLuc cells survived treatment with 10 ng/ml TGF-b1 for 48 h, the maximal inhibitory concentration (right, Figure 2a) . In response to treatment with 10 ng/ml TGF-b1, 37% of the MOLT4-shSmad7 and 87% of the MOLT4-shZEB1 cells survived. Approximately 52% of shSmad7/shZEB1-transfected MOLT4 (MOLT4-shZEB1 þ shSmad7) survived the TGF-b1 treatment, placing the survival rate of this cell line between the parental-MOLT4-shLuc and MOLT4-shSmad7 cells. We plotted the expression ratio of Smad7 and ZEB1 against the percentages of cell survival after the TGF-b1 treatment in the context of the various transfection conditions for the MOLT4 cell lines. As shown in Figure 2b , the survival rates of TGF-b1 treated MOLT4 cells, with the exception of MOLT4-shZEB1, correlated significantly with the expression ratios of Smad7 and ZEB1 (R 2 ¼ 0.9682). Almost all of the HTLV-1 ( þ ) cell lines with significantly highexpression ratios had a similar survival rate of nearly 100% (R 2 ¼ 0.7333), suggesting that cell lines with an expression ratio of Smad7/ZEB1 of more than 20-fold have a nearly 100% survival rate after TGF-b1 treatment.
To confirm whether the elevated Smad7 expression had a role in the resistance to TGF-b1 growth inhibition of HTLV-1 ( þ ) cell lines irrespective of Tax expression, we downregulated endogenous Smad7 in Tax-positive MT2 and Tax-negative KK1 cell lines by transfection of a vector expressing shSmad7. The growth of the shSmad7-transfected MT2 and KK1 cells was inhibited by TGF-b1 treatment for 48 h in a dose-dependent manner, whereas both of the parental cells and the control shLuc-transfected cells were completely resistant to the growth inhibitory action of TGF-b1 (Figures 2c  and d) . In both the Tax-positive cell lines (MT2 and Hut102; Supplementary Figure 3 ) and the Tax-negative cell lines (MOLT4 and KK1), shSmad7 transfection Figure 1 The mRNA expression profile of the Smad family. (a) Semiquantitative RT-PCR analysis for Smad2, Smad3, Smad6, Smad7 and HTLV-1 tax/rex is shown in four HTLV-1-negative (MOLT4, MKB1, KAWAI and Jurkat) and seven HTLV-1-positive (MT2, Hut102, ED, KOB, SO4, KK1 and S1T) cell lines. The expression of b-actin (ACTB) is shown at the bottom as a control. (b) Quantitative RT-PCR analysis for Smad7 and ZEB1 is shown in the four HTLV-1-negative and seven HTLV-1-positive cell lines. Smad7 and ZEB1 mRNA expression levels were normalized to b-actin mRNA expression and expressed relative to the mRNA level in a healthy control (CD4 þ T). The relative levels of Smad7 and ZEB1 expression are presented as a ratio of Smad7/ZEB1 mRNA. Student's t-test was used for the statistical analysis. (c) Quantitative RT-PCR analysis for Smad7 and ZEB1 is shown in eight patients with acute-type ATLL (ATL) and in four healthy controls (CD4 þ T). Smad7 and ZEB1 mRNA expression levels were expressed relative to the mRNA level in a healthy control. The data are presented as in Figure 1b .
ZEB1 counteracts TGF-b inhibition by Smad7 in ATLL S Nakahata et al enhanced the growth-suppression effect of TGF-b1. In addition, enforced expression of ZEB1 in many HTLV-1 ( þ ) cell lines enhanced TGF-b1 growth suppression, suggesting that Tax expression was independent of the modulation of TGF-b1 responsiveness by Smad7 and ZEB1 expression.
ZEB1 counteracts Smad7 repression of TGF-b1 signal transduction To determine how the expression of Smad6, Smad7 and/ or ZEB1 is involved in TGF-b1 signaling, we assayed the activity of the promoter in HepG2 hepatocellular carcinoma cells using a luciferase reporter plasmid with the TGF-b1-responsive elements from the PAI-1 promoter (p3TP-Lux). Co-transfection of Smad6 with the 3TP-Lux promoter vector weakly inhibited the TGF-b1-induced transcriptional activity, and co-transfection of Smad7 significantly inhibited TGF-b1-induced transcription ( Figure 3a ). Co-transfection of ZEB1 alone enhanced the TGF-b1-induced 3TP-Lux promoter activity (Figure 3b ), probably through a direct interaction with Smad3 (Postigo, 2003) . Importantly, cotransfection of ZEB1 with Smad6 or Smad7 overcame the inhibition of TGF-b1 signaling in a dose-dependent manner ( Figure 3b ). These results suggest that ZEB1 might counteract the Smad6-and Smad7-mediated inhibition of TGF-b1 growth suppression.
To determine the physical interaction between ZEB1 and I-Smad proteins, we performed co-immunoprecipitation experiments using 293T cells that were transiently transfected with ZEB1 and FLAG-tagged Smad6 or Smad7 expression plasmids. As shown in Figure 3c , ZEB1 coprecipitated with Smad6 or Smad7, indicating that ZEB1 could interact with both of the I-Smad proteins. To assess whether ZEB1 could directly modulate the Smad7-mediated inhibition of TGF-b1 signaling in ATLL cells, we evaluated the protein interaction and subcellular localization of endogenous ZEB1 and Smad7 proteins. To detect the physical interaction of endogenous ZEB1 with Smad7 or Smad3, we immunoprecipitated whole-cell lysates from MOLT4 cells treated with or without TGF-b1 for 24 h with an anti-ZEB1 antibody, and the immune complexes were 
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S Nakahata et al subjected to immunoblot analysis using an anti-Smad3 or anti-Smad7 antibody (Figure 3d ). The binding of ZEB1 to Smad3 was only detected in the presence of TGF-b1; however, Smad7 consistently co-precipitated with ZEB1 in both the absence and presence of TGF-b1. Next, to confirm the interaction and subcellular localization of endogenous ZEB1 and Smad7 proteins, both proteins in MOLT4-TALL and KK1-HTLV1 ( þ ) cell lines were immunostained with different fluorescent dyes with either anti-ZEB1 or anti-Smad7 antibody, and the labeled proteins were examined using a confocal microscope. The specificity of the antibody against Smad7 was evaluated by shRNA knockdown experiments. Smad7 was significantly reduced in the shSmad7- Figure 3 Counteraction of TGF-b1 signal transduction by ZEB1 and Smad7. (a) Smad7 expression significantly decreases the TGFb1 responsiveness of a Smad-dependent gene promoter. 3TP-Lux reporter assays were performed in HepG2 cells with co-transfection of either control pcDNA3 (À), increasing amounts of FLAG-Smad7/pcDNA3 or FLAG-Smad6/pcDNA3, and 3TP-Lux reporter plasmid plus stimulation by 5 ng/ml of TGF-b1 ( þ ) or phosphate-buffered saline (PBS) (À) for 24 h. The results are shown as the means and s.d. of triplicate transfections. The activity obtained in the absence of TGF-b1 was set at 1. (b) ZEB1 counteracts the inhibitory effects of Smad6 or Smad7. 3TP-Lux reporter assays were performed in HepG2 cells transiently transfected with pcDNA3 (À), FLAG-Smad6/pcDNA3 or FLAG-Smad7/pcDNA3, and/or increasing amounts of the ZEB1/pcDNA and 3TP-Lux reporter plasmids. Cells were stimulated with 5 ng/ml of TGF-b1 ( þ ) or PBS (À) for 24 h. (c) ZEB1 interacts with Smad6 or Smad7. 293T cells were transiently transfected with ZEB1, FLAG-Smad7 and/or FLAG-Smad6 expression plasmids, and the whole-cell lysates were immunoprecipitated with an anti-FLAG antibody. The immunoprecipitates were detected by anti-ZEB1 or anti-FLAG antibody. (d) Endogenous ZEB1 interacts with endogenous Smad7 or Smad3 in MOLT4 cells. After treatment with 10 ng/ml of TGF-b1 or PBS as control for 24 h, whole-cell lysates from MOLT4 cells were immunoprecipitated with an anti-ZEB1 antibody. The immunoprecipitates were immunoblotted using anti-Smad7 or anti-Smad3 antibody. (e, f) Subcellular localization of ZEB1 and Smad7 in the absence or presence of TGF-b1 stimulation. After MOLT4 (e) and KK1 (f) cells were treated with 10 ng/ml of TGF-b1 ( þ TGF-b1) or PBS (ÀTGF-b1) for 24 h, localization of endogenous ZEB1 and Smad7 was detected by indirect immunofluorescence using anti-ZEB1 and anti-Smad7 antibodies. The proteins were visualized using an Alexa Fluor 488-conjugated anti-goat secondary antibody (green, for ZEB1) and the Alexa Fluor 555-conjugated anti-rabbit secondary antibody (red, for Smad7). The cells were analyzed using confocal microscopy, and the DAPI (4,6-diamidino-2-phenylindole) stain was used to visualize the nuclei.
ZEB1 counteracts TGF-b inhibition by Smad7 in ATLL S Nakahata et al treated cells but not in the shLuc-transfected cells by immunoblots and immunofluorescent staining (Supplementary Figure 4) . In MOLT4 cells, ZEB1 and Smad7 were mainly colocalized in the nucleus (Figure 3e ), confirming the protein interaction between endogenous ZEB1 and Smad7 (Figure 3d ). Nuclear localization of Smad7 was also observed in the KK1-HTLV1 ( þ ) cell line (Figure 3f ). Therefore, ZEB1 may directly modulate the inhibitory function of Smad7 in the nucleus.
Association of ZEB1 with Smad7 or Smad3
To investigate the function of ZEB1 in the TGF-b1 signaling pathway, we initially examined the physical interactions between ZEB1, Smad3 and Smad7 with or without TGF-b1 treatment in HepG2 cells using immunoprecipitation and western blot. This was done because both the exogenously expressed ZEB1 and Smad7 were located in the nucleus regardless of TGF-b1 treatment (Supplementary Figure 5) . In the absence of TGF-b1 treatment, neither the Smad3-ZEB1 nor Smad3-Smad7 interaction was observed by the coprecipitation assay using the corresponding specific antibody. After TGF-b1 treatment, Smad3 could be precipitated with ZEB1, but not with Smad7 (Supplementary Figure 6a ). By contrast, Smad7 was constitutively associated with ZEB1 in HepG2 cells irrespective of TGF-b1 treatment (Supplementary Figure 6b) . To identify the binding domain in Smad7 that was responsible for the interaction with ZEB1, we generated two Flag-tagged deletion mutants of Smad7: Smad7-N, which encoded the first half of Smad7 (amino acids 1-259), and Smad7-MH2, which encoded the second half of Smad7 containing the Mad-homology 2 (MH2) domain (amino acids 260-420) ( Figure 4a ). As shown in Figure 4b , ZEB1 did not coprecipitate with Smad7-N; however, ZEB1 did coprecipitate with Smad7-MH2. This suggests that ZEB1 interacts with the MH2 domain of Smad7. The Smad-interacting domain (SID) of ZEB1 has been reported to interact with Smad1, Smad2 or Smad3 in the nucleus after treatment with TGF-b1 (Postigo, 2003) . Therefore, to determine which region of ZEB1 was necessary for binding to Smad7, three deletion mutant plasmids and a full-length ZEB1 expression plasmid were generated (Figure 4a ): a fulllength ZEB1-GFP fusion construct (GFP-ZEB1), GFP fused to the N-terminal domain (amino acids 1-377; ZEB1-N), GFP fused to the SID (amino acids 378-457; ZEB1-SID) and GFP fused to the C-terminal domain (amino acids 458-1125; ZEB1-C). As shown in Figure 4c , only ZEB1-SID precipitated with Smad7 protein, suggesting that Smad7 interacts with the SID domain of ZEB1.
Because the SID region of ZEB1 interacts with both Smad3 and Smad7, it is possible that these two proteins compete for ZEB1 in the nucleus after TGF-b1 stimulation. To test this possibility, we transfected HepG2 cells with expression plasmids encoding three genes (HA-Smad3, GFP-Smad7 and FLAG-ZEB1) in various combinations and treated with TGF-b1. As shown in Figure 4d , the ZEB1/Smad3, ZEB1/Smad7 and ZEB1/Smad3/Smad7 complexes could all be detected. The same interaction experiment was repeated with the difference being that the full-length ZEB1 expression plasmid was replaced with a plasmid expressing solely the SID region of ZEB1 (GFP-ZEB1-SID). As shown in Supplementary Figure 7 , the ZEB1-SID coprecipitated with Smad3, Smad7 and a complex of Smad3 and Smad7. Because Smad3 and Smad7 have not been shown to interact with each other, these data suggest that the SID region of ZEB1 may simultaneously interact with both Smad3 and Smad7. To assess this possibility, we immunoprecipitated lysates from cells transfected with HA-Smad3, FLAG-Smad7 and ZEB1 in the presence of TGF-b1 with either anti-HA or anti-FLAG antibody and coprecipitation of these three proteins was examined. As shown in Figure 4e , the ZEB1/Smad3/Smad7 complexes were identified in both anti-HA (Smad3) and anti-FLAG (Smad7) immunoprecipitates. We also performed a competitive binding experiment using cells that were co-transfected with a fixed amount of ZEB1-SID and Smad3 expression plasmids and increasing amounts of Smad7 expression plasmid (Figure 4f ). After immunoprecipitation of GFP-ZEB1-SID, the ZEB1/SID/Smad3 complex could be detected regardless of the amount of Smad7 expression plasmid that was transfected into the cell. In the converse experiment, ZEB1/SID/Smad7 complex could be detected regardless of the amount of Smad3 expression plasmid that was transfected into the cells (Supplementary Figure 8) . Therefore, regulatory Smad3 (R-Smad3) and I-Smad7 were able to bind to the ZEB1-SID region without competition.
Binding of the 3TP promoter region by a transcription factor complex of Smad3, Smad7 and ZEB1 after TGF-b1 stimulation To investigate the transcriptional regulation by ZEB1 and the Smad proteins, we performed chromatin immunoprecipitation (ChIP) in HepG2 cells co-transfected with the p3TP-Lux and expression plasmids encoding HA-Smad3, FLAG-Smad7 and/or ZEB1. Formaldehyde crosslinked DNA isolated from transfected HepG2 cells was immunoprecipitated using the indicated antibody and subjected to semiquantitative PCR with primers specific for the 3TP promoter. After the transfection of HepG2 cells with the HA-Smad3 expression plasmid, we treated the cells with TGF-b1, and precipitated DNA fragments that bound to the protein complex with either an anti-HA (Smad3), antip300 or anti-HDAC1 antibody. Treatment with TGFb1 induced a dramatic increase in the binding of the 3TP promoter region by both Smad3 and p300 (Figure 5a ). Upon transfection of FLAG-Smad7 in either the absence or presence of TGF-b1, the Smad7 and HDAC1 complex was constantly bound to the 3TP promoter (Figure 5b ). In addition, when HA-Smad3 and FLAGSmad7 were co-transfected in the presence of TGF-b1 (Figure 5c ), the Smad7/HDAC1 complex was found bound to the 3TP promoter; however, binding of the Smad3 and p300 complex to the promoter was ZEB1 counteracts TGF-b inhibition by Smad7 in ATLL S Nakahata et al decreased. When cells were co-transfected with ZEB1, Smad3 and Smad7 in the presence of TGF-b1 (Figure 5d ), the binding of Smad3 and p300 was clearly increased to similar levels as that seen with Smad3 transfection alone, while the occupancy of HDAC1 was decreased. The recruitment of ZEB1 to the 3TP promoter region is mediated by its interaction with Smad3 or Smad7, because no signal was detected when the cells were transfected with ZEB1 alone (Supplementary Figure 9 ). To examine whether ZEB1 expression in HTLV-1 ( þ ) cell lines results in the binding of the Smad7/ZEB1/Smad3/p300 complex to the 3TP promoter region following TGF-b1 stimulation, we performed ChIP in MT2 cells that were co-transfected with the interacts with Smad3 and Smad7. After transfection with FLAG-ZEB1, GFP-Smad7 and HA-Smad3 into HepG2 cells, the cells were treated with 5 ng/ml of TGF-b1 for 24 h. Cell lysates were precipitated by anti-FLAG antibody. The precipitates were immunoblotted by an anti-HA, anti-GFP or anti-FLAG antibody. (e) ZEB1 simultaneously interacts with both Smad3 and Smad7. After transfection with ZEB1, FLAG-Smad7, and HA-Smad3 into HepG2 cells, the cells were treated with 5 ng/ml of TGF-b1 for 24 h. Cell lysates were precipitated by either anti-FLAG or anti-HA antibody. The precipitates were immunoblotted by an anti-HA, anti-FLAG or anti-ZEB1 antibody. (f) Smad3 and Smad7 interact with ZEB1 in a noncompetitive manner. After transfection with GFP-ZEB1-SID, FLAG-Smad3 and/or increasing amounts of FLAG-Smad7 into HepG2 cells, the cells were treated with 5 ng/ml of TGF-b1 for 24 h and the cell lysates were immunoprecipitated with an anti-GFP antibody.
ZEB1 counteracts TGF-b inhibition by Smad7 in ATLL S Nakahata et al Figure 5 Smad7, ZEB1 and Smad3 are present in the transcription factor complex that binds to the Smad-responsive promoter.
(a) Specific binding of Smad3 to the 3TP-Lux promoter upon TGF-b1 stimulation. After transfection with pcDNA3 (Mock) or HA-Smad3 and p3TP-Lux into HepG2 cells, the cells were treated with 5 ng/ml of TGF-b1 ( þ TGF-b1) or phosphate-buffered saline (PBS) (ÀTGF-b1) for 16 h. The cells were fixed with formaldehyde, sonicated and the chromatin fraction was immunoprecipitated using anti-HA, anti-p300 or anti-HDAC1 antibody. The precipitated DNA and 1% of the input cell lysates were amplified by PCR using specific primers for the 3TP-Lux promoter. As a control, the expression level of HA-tagged Smad3 protein was confirmed by western blot using an anti-HA antibody (IB). (b) Smad7 constantly binds to the 3TP-Lux promoter in either the presence or absence of TGF-b1. After transfection with pcDNA3 (Mock) or FLAG-Smad7 with p3TP-Lux and treatment with 5 ng/ml of TGF-b1 ( þ TGF-b1) or PBS (ÀTGF-b1) for 16 h, the HepG2 cells were chromatin immunoprecipitated (ChIP) by each indicated antibody. The precipitated DNAs were amplified by the 3TP promoter-specific primers. Smad7 protein expression was identified by an anti-FLAG antibody (IB). (c) Smad7 inhibits the DNA-binding of Smad3 and p300. HepG2 cells were transfected with p3TP-Lux and either empty vector (Mock) or plasmid vectors expressing HA-Smad3 and/or FLAG-Smad7 and treated with 5 ng/ml of TGF-b1 for 16 h. The cell lysates were subsequently subjected to ChIP with the indicated antibodies and precipitated DNAs were amplified using PCR for the 3TP promoter. A control western blot of the transfected cells is shown at the bottom (IB). (d) ZEB1 recruits the Smad3/p300 complex to the 3TP-Lux promoter. HepG2 cells were co-transfected with the expression vectors for HA-Smad3, FLAG-Smad7 and/or ZEB1, and p3TP-Lux plasmid and treated with 5 ng/ml of TGF-b1 for 16 h. The cell lysates were analyzed using ChIP. After immunoprecipitation with each indicated antibody, the 3TP promoter region was amplified by PCR using specific primers. A control western blot of the transfected cells is also shown. (e) Ectopic expression of ZEB1 causes efficient recruitment of the Smad3/p300 complex to the 3TP-Lux promoter in HTLV-1 ( þ ) cell lines. MT2 cells were transfected with p3TP-Lux and either empty vector (Mock) or ZEB1 expression vector and treated with 10 ng/ml of TGF-b1 for 24 h. The cell lysates were subjected to ChIP analysis with the indicated antibodies and primers specific for the 3TP promoter. A western blot of the transfected cells is shown in the left panel.
ZEB1 counteracts TGF-b inhibition by Smad7 in ATLL S Nakahata et al p3TP-Lux and ZEB1 expression plasmids (Figure 5e ). In the absence of TGF-b1, Smad7, ZEB1 and HDAC1 were detected on the 3TP promoter region; however, recruitment of Smad3 and p300 were detected along with a decrease of HDAC1 binding after TGF-b1 treatment. In Mock-transfected cells, protein complex of Smad7 and HDAC1 bound to the 3TP promoter region regardless of TGF-b1 treatment. To assess the possibility that ZEB1 might interfere with the interaction between Smad7 and HDAC1, we co-transfected GFP-Smad7 and FLAG-HDAC1 expression plasmids with increasing amounts of the ZEB1 expression plasmid and subjected to co-immunoprecipitation using the anti-GFP antibody (Supplementary Figure 10) . The HDAC1/Smad7 complex was clearly detected in the absence of ZEB1 transfection; however, the level of the HDAC1/Smad7 complex was decreased when increasing amounts of the ZEB1 expression vector were transfected with both the GFP-Smad7 and FLAG-HDAC1 expression plasmids. These results suggest that ZEB1 recruits the Smad3/p300 complex to the 3TP promoter with the activation of TGF-b1 signal transduction despite the presence of Smad7 on the 3TP promoter region.
ZEB1 expression extended the duration of PAI-1 and p21 transcriptional activation by TGF-b1 signaling in lymphoid cells The expression of I-Smads is quickly induced upon stimulation by TGF-b, and I-Smads may be part of the negative feedback control mechanism. We used semiquantitative RT-PCR to initially determine the expression pattern of ZEB1 and ZEB2, members of the zincfinger E-box binding homeobox protein (ZFHX) family, in various hematopoietic cell populations. ZEB1 was expressed in the B-and T-cell populations in the spleen and the CD4 þ CD8 þ DP, CD4 þ SP and CD8 þ SP T cells in the thymus (Figure 6a) ; however, ZEB2 was weakly expressed in the B-cell fraction in the spleen. Therefore, ZEB1 appears to have an important role in the late stages of T-cell development. To examine how ZEB1 expression modulates TGF-b1 signaling, we used the murine interleukin-2 (IL-2)-dependent T-lymphoma cell line CTLL2, which has high expression of ZEB1 and low or no expression of Smad7, for this experiment. CTLL2 is known to be one of the T-cell lines that is highly responsive the treatment of TGF-b1, showing a decrease in cell viability to approximately 40%, compared to the control 2 days after TGF-b1 stimulation (Inge et al., 1992; Hidaka et al., 2008) . To investigate the role that ZEB1 has in TGF-b1 signaling in CTLL2 cells, we transfected the cells with a ZEB1 shRNA vector (CTLL2-shZEB1) or a luciferase shRNA vector, which served as a control (CTLL2-shLuc), and examined the TGF-b1-induced transcription of Smad6, Smad7, PAI-1 and p21 by semiquantitative and quantitative RT-PCR. As previously reported, survival rates of CTLL2-shZEB1 cells increased to 60% after treatment with TGF-b1 (data not shown, Hidaka et al., 2008) . As shown in Figure 6b , treatment of TGF-b1 immediately induced Smad6 and Smad7 transcription as early as 30 min, and PAI-1 mRNA was induced 1 h after TGF-b1 treatment. Peak expression of PAI-1 mRNA in parental and CTLL2-shLuc cells continued for 12 h and then decreased to background levels 24 h after TGF-b1 treatment (Figure 6b) . Similarly, in CTLL2-shZEB1 cells, PAI-1 mRNA was induced 1 h after TGF-b1 treatment with a similar level of PAI-1 mRNA as in control cells. However, the downregulation of PAI-1 mRNA began as early as 4 h and continued to decrease to background levels at 12 h after TGF-b1 treatment (top, Figure 6c) . Conversely, the expression of p21 mRNA started to increase at 4 h after TGF-b1 treatment, whereas the peak was half that of control CTLL2 cells. Moreover, the highest expression level of p21 lasted from 4 to 24 h in control cells; whereas that duration was shortened to 4-12 h in CTLL2-shZEB1 cells (bottom, Figure 6c) . Thus, ZEB1 expression in CTLL2 cells extended the duration of TGF-b1 signaling up to 24 h after TGF-b1 treatment. Because the duration of Smad3 phosphorylation in CTLL2-shZEB1 cells was not significantly different from those in the control cells (Supplementary Figure 11) , it appears that ZEB1 expression may enhance TGF-b1 signaling without affecting Smad3 phosphorylation in CTLL2 cells. To confirm the colocalization of ZEB1 and Smad7 in CTLL2 cells, we visualized both proteins by immunofluorescence, at the indicated times, after TGF-b1 treatment. ZEB1 constitutively localized to the nucleus, and Smad7, which was induced after TGF-b1 treatment, was also predominantly localized to the nucleus (Figure 6d ). To confirm the protein complex of endogenous Smad3, Smad7 and ZEB1 on the TGF-b1 responsive promoter in CTLL2 cells after TGF-b1 treatment, we used ChIP using the corresponding specific antibody. Protein complex of Smad3, Smad7 and ZEB1 bound to the p21 promoter in CTLL2 cells 12 h after TGF-b1 stimulation (top, Figure 6e ). To confirm that Smad7 directly binds to the SRE in the p21 promoter region, we constructed p21 promoter reporter with mutated SRE for analyses of ChIP and the promoter activity induced by TGF-b1 (Seoane et al., 2004) . The mutated SRE in the p21 promoter region totally abolished the DNA-binding activity of Smad7 by ChIP analysis (Figure 6f ) and the level of the promoter activity was significantly reduced after TGF-b1 stimulation (Supplementary Figure 12) , suggesting that Smad7 directly binds to the SRE with recruitment of the Smad3/ZEB1 complex. In MOLT4 cells, Smad7 and ZEB1 associated with the p21 promoter regardless of TGF-b1 treatment and Smad3 recruitment could be detected upon stimulation with TGF-b1 (bottom, Figure 6e ). Furthermore, knockdown of ZEB1 diminished the recruitment of Smad3 to the protein complex on the p21 promoter in CTLL2 cells (Figure 6g ), thus suggesting that ZEB1 was necessary for keeping Smad3 in the protein complex on the p21 promoter with SRE to elongate the active status of TGF-b1 signaling. Figure 7a illustrates a model for the ZEB1-dependent transcriptional control in the TGF-b1 signaling pathway in CTLL2 cells. As a negative feedback mechanism, the expression of Smad7 is induced within 1 h of TGF-b1 ZEB1 counteracts TGF-b inhibition by Smad7 in ATLL S Nakahata et al stimulation by Smad signal transduction pathways. The phosphorylated Smad3 cooperates with p300 and ZEB1 to activate many cellular genes within 1-12 h after TGF-b1 stimulation, including PAI-1 and p21, through its ability to interact with several transcription factors, even though Smad7 protein accumulates in the cells at the later stages of development. When ZEB1 expression was downregulated by transfection with shZEB1, phosphorylated Smad3 could not bind to the p21 promoter with SRE, which due to Smad7 interference, and p21 transcription is shut off 4-12 h after TGF-b1 stimulation (Figure 7b ). In the MOLT4 cell line, high expression of ZEB1 recruits phosphorylated Smad3 complex to the p21 promoter region with the constitutive expression of Smad7, and weakly maintains TGF-b1 signaling with a survival rate of approximately 70% (Figure 7c ). In HTLV-1 ( þ ) cells, constitutive binding of Smad7 protein to the p21 promoter region with SRE interferes with phosphorylated Smad3 complex to block TGF-b1 signaling, and most of the HTLV-1 ( þ ) cells could survive after TGF-b1 treatment (Figure 7d ).
Discussion
In this report, we showed that TGF-b signaling is enhanced by ZEB1, which binds to both R-Smads and I-Smads. Transcription of inhibitory I-Smad6 and I-Smad7 is immediately induced by the binding of ZEB1 counteracts TGF-b inhibition by Smad7 in ATLL S Nakahata et al phosphorylated R-Smads to the promoter of Smad6 and Smad7 after TGF-b signaling. TGF-b signaling is suppressed by I-Smads in a negative feedback mechanism. In lymphoid cells, Smad7 is localized on the promoter with the SREs in the nucleus to suppress TGF-b signaling following induction of TGF-b; however, ZEB1 recruits the phosphorylated R-Smad complex to the promoter and enhances TGF-b signaling. Thus, ZEB1 may have important roles in the regulation of TGF-b1 signaling by binding to R-Smads and I-Smads. Moreover, while analyzing the molecular mechanism of resistance to TGF-b signaling in ATLL, we identified that both ZEB1 downregulation and Smad7 overexpression contribute to the TGF-b resistance. Several reports have described the mechanism by which I-Smads inhibit TGF-b1 signaling. I-Smads located in the cytoplasm have been reported to bind TGF-b type I receptors, recruit E3 ubiquitin ligases (Smurfs) to type I receptors or bind to phosphorylated Smad1 and inhibit the formation of the R-Smad/Co-Smad complex (Hata et al., 1998; Souchelnytskyi et al., 1998; Kavsak et al., 2000; Ebisawa et al., 2001) . Conversely, I-Smads 
þ T-lymphoid cells from the thymus of adult mice. The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is shown at the bottom as a control. (b) CTLL2 cells were untransfected (Parental) or transfected with the control luciferase-specific shRNA vector (shLuc), or the ZEB1-specific shRNA vector (shZEB1) and then treated with 10 ng/ml of TGF-b1. Total RNA was isolated at the indicated time points and semiquantitative RT-PCR was performed with specific primers for ZEB1, Smad6, Smad7, PAI-1, p21 and b-actin. (c) Quantitative real-time PCR analysis of PAI-1 (top) and p21 (bottom) mRNA expression in the same conditioned CTLL2 cell lines as b. Student's t-test was used for the statistical analysis, and Po0.05 (asterisk) was considered significant. (d) Subcellular localization of ZEB1 and Smad7 in the CTLL2 cell lines at the indicated time periods after treatment with 10 ng/ml of TGF-b1. The localization of endogenous ZEB1 and Smad7 was detected by indirect immunofluorescence using an anti-ZEB1 (green, Alexa Fluor 488) and anti-Smad7 antibody (red, Alexa Fluor 555) using the same strategy as described in Figure 3 . The cells were analyzed by confocal microscopy, and a DAPI (4,6-diamidino-2-phenylindole) stain was used to visualize the position of the nuclei (blue). (e) Protein complex of Smad3, Smad7 and ZEB1 bound to the p21 promoter after TGF-b1 treatment. Chromatin from CTLL2 (top) and MOLT4 (bottom) cells treated with or without 10 ng/ml of TGF-b1 for 12 h was immunoprecipitated with antibodies against Smad3, Smad7, ZEB1 or normal rabbit serum (as negative controls) and immunoprecipitated DNA was analyzed by PCR using the indicated primer pairs. PCR using primers specific for the b-actin (ACTB) promoter was included for the specificity of the ChIP assay. (f) CTLL2 cells were co-transfected with a p21-Luc or p21-Luc/SREmut reporter construct and/or expression vectors for either HA-Smad3 or FLAG-Smad7 and treated with 10 ng/ml of TGF-b1 for 12 h. The cell lysates were analyzed using ChIP. A control western blot of the transfected cells is also shown. (g) Occupancy of Smad3 is reduced in the protein complex on the p21 promoter with SRE in CTLL2-shZEB1 cells. CTLL2 cells were transfected with the control shRNA vector (shLuc), or the ZEB1-specific shRNA vector (shZEB1) and treated with 10 ng/ml of TGF-b1 for 12 h. The cell lysates were analyzed using ChIP. Semiquantitative RT-PCR for ZEB1 and b-actin mRNA are shown at the top panel. ZEB1 counteracts TGF-b inhibition by Smad7 in ATLL S Nakahata et al that reside in the nucleus interact with the transcriptional co-repressors Hoxc-8 or CtBP to inhibit BMPinduced transcription or bind to DNA to competitively inhibit the formation of the Smad/DNA complex (Bai et al., 2000; Lin et al., 2003; Zhang et al., 2007) . In ATLL cells, Smad7 predominantly localizes to the nucleus and binds to the promoter region of TGF-b1 responsive genes with SRE to inhibit formation of the R-Smad/DNA complex. The differential localization of Smad7 between cell types is currently unknown; however, Smurf-mediated nuclear export of Smad7 has been shown in several studies (Kavsak et al., 2000; Suzuki et al., 2002) . In our study using DNA microarrays, we found that the expression level of Smurf1 in acute-type ATLL cells was higher than in CD4 þ T lymphocytes from normal volunteers; however, the expression of Smurf2 was lower in ATLL cells (data not shown). Therefore, further studies are needed to clarify the mechanism of Smad7 nuclear localization in ATLL cells.
I-Smads have important roles in the negative feedback mechanism of Smad signaling, and protein phosphatase 1A was recently identified as a Smad phosphatase that terminates TGF-b1 signaling (Lin et al., 2006) . Protein phosphatase 1A enhances the disassembly of the activated Smad complex by dephosphorylation of TGF-b1-activated Smad2/3 and promotes nuclear export of dephosphorylated Smad2/3. In T lymphocytes, transcriptional activation by TGF-b1 signaling was terminated within 24 h in both the control CTLL2 and CTLL2-shZEB1 cells, suggesting that protein phosphatase 1A terminates TGF-b1 signaling within 24 h. However, expression of ZEB1 in CTLL2 cells elongated the duration of TGF-b1-induced transcriptional activation of PAI-1 and p21 to overcome the suppressor activity of I-Smad6 and I-Smad7 until 24 h. Therefore, we speculate that the elongation of TGF-b1 signaling by ZEB1 is necessary for suppression of the cell growth of T lymphocytes during T-cell differentiation by TGF-b1.
In this study, we showed that ZEB1 interacts with both R-Smads and I-Smads to enhance TGF-b1 signaling and counteracts the Smad7-mediated inhibition of TGF-b1 signaling. We showed that ZEB1 is specifically expressed in CD4 þ CD8 þ DP lymphocytes through CD4 þ SP T lymphocytes (Figure 6a ), and ZEB-1-deficient mice frequently develop CD4 þ T-lymphoma/ leukemia (Hidaka et al., 2008) . This suggests that the expression of ZEB1 during the late stages of T-cell differentiation is necessary for enhancing the growthinhibitory effect of TGF-b1 on CD4 þ T cells. In addition, recent studies have shown that in Se´zary syndrome, an aggressive cutaneous T-cell lymphoma/ leukemia, genomic deletion of ZEB1 has been detected in approximately half of patients (Vermeer et al., 2008) . Although Smad7 overexpression has not yet been reported in Se´zary syndrome, downregulation of ZEB1, in combination with Smad7 overexpression, may be an important event for the development of peripheral types of T-cell leukemia/lymphoma.
